Organic compositions to treat APOC3-related diseases
US10240153B2 · kind B2 · utility
4Cited by
7References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 11, 2017 |
| Grant date | Mar 26, 2019 |
| Priority date | — |
| Expiry date | Jan 11, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to compositions and methods for treating APOC3-related diseases such as: hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.